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Epilepsy is a  chronic neurological disease characterized by recurrent seizures that affects about 70 million people worldwide. 
Antiepileptic drugs are the most commonly used medications in the treatment of epilepsy. They help control seizures in about 60‑70% 
of people. The remaining percentage of patients suffer from drug‑resistant epilepsy, prompting scientists to look for natural substances 
that would prevent seizures or support the effects of drugs in add‑on therapy while reducing side effects. Currently, there is a lot of 
emphasis on natural product. Flavonoids are included in this group, and their use in the treatment of epilepsy could support the effect 
of other drugs. Due to very good results of preclinical studies, flavonoids are a promising candidate for epilepsy related clinical trials 
related. The article is an overview of literature reports from the past 10 years including mainly in vivo preclinical research on various 
models of experimental epilepsy with the use of selected flavonoids.
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INTRODUCTION
Epilepsy is a serious neurological disorder affecting 
around 70 million people around the world. Antiepi‑
leptic drug (AED) therapy is effective in 60–70% of pa‑
tients, however in 30‑40% of patients seizure control 
is not achieved (Kalilani et al., 2018). Drug resistance 
in epilepsy is defined by International League Against 
Epilepsy as the failure of treatment with two properly 
used and well‑tolerated AEDs (both, monotherapy and 
combination) used for a sufficiently long time in con‑
trolling seizures (Kwan et al., 2010). The mechanism of 
drug resistance is not fully known or fully explained. 
It is probably influenced by both genetic and environ‑
mental factors (Tang et al., 2017). For those suffering 
from drug‑resistant epilepsy (DRE) numerous drug 
side effects, memory disorders, stigmatization become 
a social problem, and the lack of expected treatment 
effects contribute to the occurrence of depression in 
even half of the patients (Kozera‑Kępniak et al., 2013). 
Sudden unexpected death in epilepsy (SUDEP) is the 
main cause of death in patients with DRE and accounts 
for up to 50% documented causes of death in this group 
of patients (Opeskin and Berkovic 2003; Tomson et al., 
2008; Surges et al., 2009; Shorvon and Tomson, 2011). 
Therefore, the main goal of DRE therapy is to extend 
the seizure control period, minimize side effects and 
improve quality of life (Boon et al., 2015). Currently, 
a number of scientific studies include the use of natu‑
ral substances with antiepileptic properties as adjuncts 
to standard antiepileptic drugs in the DRE treatment 
and flavonoids and may be a potential group of natural 
drugs that increase the effects of commonly used anti‑
convulsants.
Flavonoids, a class of secondary plant metabolites, 
have been shown to demonstrate a wide spectrum of 
biological activity, among others antioxidant (Santos et 
al., 1999), anti‑inflammatory (Pintho et al., 2016), anti‑
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allergic (Kawai et al., 2006), antiatherosclerotic (Gold‑
wasser et al., 2011), antidiabetic (Rayidi et al., 2011) as 
well as hepatoprotective (Renugadevi et al., 2009). Cor‑
sale et al. (2018) used a mixture of flavonoids such as 
diosmin, troxerutin, rutin, hesperidin, and quercetin to 
reduce bleeding due to hemorrhoidal disease. Cicero et 
al. (2019) evaluated the effectiveness of bergamot fla‑
vonoid extract in people with dyslipidemia and those 
overweight. Obtained results showed an improvement 
in lipid and glucose metabolism, adipokine pattern 
and systemic inflammation in overweight and dyslip‑
idemic individuals. Kirienko et al. (2018) investigated 
the clinical efficacy of 1000 mg micronized purified fla‑
vonoid fraction (MPFF) administered once daily in pa‑
tients with chronic venous disease (CVD), which turned 
out to be associated with a rapid reduction in leg pain 
throughout the 8‑week treatment period.
Flavonoids are derivatives of 2‑phenyl‑benzo‑γ‑py‑
rone. A common part in the chemical structure of all 
flavonoids is the carbon skeleton based on the flavane 
system (C6‑C3‑C6), formed from two benzene rings (A 
and B) connected by a heterocyclic ring of pyran or 
pyrone (C) (Fig. 1, Pietta, 2000). The biosynthesis of A 
and B rings occurs in two pathways – acetate (A) and 
shikimate (B). Ring A is formed from 3 malonyl‑CoA 
molecules obtained from glucose conversions. Ring B 
is formed from 4‑coumaroyl‑CoA, created in the shi‑
kimate pathway from phenylalanine. Condensation of 
the A and B ring leads to the formation of chalcone, 
which is cyclized with the participation of isomerase 
and forms flavanone ‑ the initial compound for the syn‑
thesis of the remaining flavonoid groups (Bravo et al., 
1998, Wang et al., 2018). They may exist in free form 
of aglycone or betaglycosides (Panche et al., 2016). Due 
to differences in the structure, flavonoid compounds 
are divided into several subclasses: flavanones, flavo‑
nols, flavones, isoflavones, chalcones and anthocyanins 
(Table I.) The article focuses on several compounds 
from the flavonoid group that have been shown to pos‑
sess antiepileptic properties in various experimental 
models of epilepsy (Table II).
Anticonvulsant properties of flavonoids
Naringenin/naringin
Naringenin (2,3‑dihydro‑5,7‑dihydroxy‑2‑(4‑hy‑
droxyphenyl)‑4H‑1‑benzopyran‑4‑one, Fig. 2) is 
a natural phenolic compound found in citrus species 
and Chinese plants such as: Drynaria fortunei, Citrus au-
rantium and Citrus medica (Jadeja et al., 2014; Chen et 
al., 2016). Shakeel et al. (2017) indicated anticonvul‑
sant properties for naringenin in the mouse pilocar‑
pine‑induced seizures (PILO). Results they obtained 
showed that 15‑day treatment naringine (20 mg/kg 
and 40 mg/kg), followed by the administration of pilo‑
carpine on the last day of treatment, seizures reduced 
in comparison with the control group. Naringenin has 
been shown to inhibit the onset and duration of sei‑
zures in a dose‑dependent manner. Naringin in a dose 
of 20 mg shortened the seizure duration by about 
1 min, and delayed seizures by 12 min, whereas the 
Fig. 1. The main structure of flavonoids with rings and numbered positions.
Table I. Flavonoids – subclasses division.
Flavonoids
Flavonols Flavanones Flavones Isoflavones Chalcones
quercetin 
naringenin apigenin daidzein phloretin
routine
kemferol naringin diosmetin genistein arbutin
mirecitin hesperidin luteolin phloridzin
fistein hesperedine baicalin chalconaringenin
morina
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higher dose (40 mg/kg) shortened seizure duration 
by 2 min and delayed seizures by 27 min. Moreover, 
naringenin treatment restored the antioxidant status 
and reduced lipid peroxidation in hippocampus of ep‑
ileptic mice.
Park et al. (2016) using a kainic acid (KA) mouse 
model of temporal lobe epilepsy (TLE) showed that 
treatment with naringenin (100 mg) significantly de‑
layed the occurrence of KA‑induced seizures and im‑
paired granular cell dispersion (GCD). Moreover, the 
effects of naringenin treatment were similar to those 
of rapamycin (RA) treatment. RA is not a universal an‑
tiepileptic drug and it’s use is limited to tuberous scle‑
rosis. In these studies, it was used as a positive control 
for changes in GCD mediated by mTORC1 inactivation. 
Nissel staining showed that naringenin significantly 
reduced changes in GCD, suggesting that it may act by 
inhibiting mTORC1 pathway activation. Many studies 
have indicated that hyperactivation of the mTORC1 
pathway leads to epilepsy (Laplante et al., 2012; Sha et 
al., 2012; Lasarge et al., 2014; Shima et al., 2015). Im‑
munofluorescence results and Western blot analysis 
showed that naringenin treatment attenuated the in‑
crease in TNFα and IL‑1β expression and significantly 
reduced their levels within the dentate gyrus (DG) of 
the hippocampus of KA‑treated mice. These results 
Table II. Antiepileptic properties of selected flavonoids in animal models of epilepsy – a summary of scientific reports.
Flavonoids Animal model Results Author
Naringenine
PILO‑model (mice) • reduction of seizures Shakeel et al. (2017)
KA‑model (mice/rats) •  reduction of seizures, undisturbed 
cognitive functions
Park et al. (2016)
Golechha et al. (2011).
PTZ‑model (rats) •  protection against seizures, reduction 
of cognitive impairment Golechha et al. (2014)
Apigenin
picrotoxin‑induced seizures (mice) • delayed the onset of seizures Avallone et al. (2000)






•  delayed the onset of myoclonic jerks, 
onset of clonic seizures and onset of hind 
limb extension
• protection against mortality
• neuroprotective effect
Tambe et al. (2015)





•  delayed the onset of seizures and 
shortened the duration of clonic seizures
• improvement of cognitive functions
Smillin et al. (2020) 
 
Epigallocatechin
PTZ‑ kindling model (rats) •  reduced cognitive deficits and oxidative 
damage
Xie et al. (2012) 
cocaine‑induced seizures (rats) • reduction of seizures Park et al. (2001)
lithium‑PILO model of TLE (rats) 
 
•  reduction of the frequency of 
spontaneous recurring seizures
• neuroprotective effect





•  increased anticonvulsant effect alone 
and in combination with diazepam
• neuroprotective effect
Kumar et al. (2014)
Rosa‑Falero et al. (2015) 
Quercetin/routine
PTZ‑kindling model (rats/mice) • attenuation of seizures
• memory improvement
Nassiri‑Asl et al. (2013)
Singh et al. (2017)
PTZ model (rats) • reduced generalized seizure Sefil et al. (2014)
MEST (mice) • reduced seizures Nieoczym et al. (2014)
6 Hz model (mice) 
 
• reduced seizures
•  no side effects in behavioral tests 
in combination with LEV and VPA
Nieoczym et al. (2014) 
 
Baicalin
PILO‑model (rats) • significant delay in seizures
• reduced neuronal death
Liu et al. (2012) 
KA‑model (mice) • neuroprotective effect Liao et al. (2016)
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suggest that naringenin may have anti‑inflammatory 
effects in the KA‑induced TLE model. 
Interestingly, a flavanone glycoside naringin was 
tested in the KA induced epilepsy model in rats (Go‑
lechha et al., 2011). Results they obtained indicated, 
that initial treatment with naringin at doses 20, 40, 
80 mg/kg significantly increased seizure delay com‑
pared to the KA control group, which suggests that 
naringin suppresses KA‑induced seizures. Behavioral 
studies in the passive avoidance test showed cognitive 
impairment in the KA control group, while pretreat‑
ment with naringin reversed the KA‑induced cognitive 
deficit (Golechha et al., 2011). Additionally, in the rat 
pentylenetetrazol (PTZ) model naringin (20, 40 and 
80 mg/kg) administered for 7 days significantly delayed 
the occurrence of myoclonic seizures depending on the 
dose (Golechha et al., 2014). Obtained results indicated 
that treatment with naringin (80 mg/kg) protected all 
rats against PTZ seizures, and reduced brain malondi‑
aldehyde and TNF‑α levels and conserved glutathione, 
which highlighted the antioxidant, anti‑inflammatory 
and anticonvulsant potential of naringin. Additional 
studies were conducted in order to check whether the 
anticonvulsant effect of naringin is GABA dependent. 
For this purpose, the GABA‑A receptor was blocked by 
flumazenil, an antagonist of GABA‑A. Obtained results 
showed, that flumazenil pretreatment decreased the 
prolongation of convulsant latency induced by nar‑
ingin, suggesting a possible modulation of the benzodi‑
azepine site of the GABA‑A receptor by naringin to pro‑
duce its anticonvulsant effect (Golechha et al., 2014).
Compans and coworkers (2018) investigated a po‑
tent anticonvulsant properties of two methylated fla‑
vanones: naringenin 4’,7‑dimethyl ether (NRG‑DM) 
and naringenin 7‑O‑methyl ether (NRG‑M) in zebrafish 
pentylenetetrazole (PTZ) seizure model. Results they 
obtained showed, that both NRG‑M NRG‑DM decreased 
PTZ‑induced seizure activity in larval zebrafish up to 
approximately 20‑30% compared to PTZ controls. In 
addition, NRG‑DM was shown to be active in two stan‑
dard mouse models of acute epilepsy, the PTZ test and 
in the 6 Hz psychomotor seizure model, suggesting 
that methylation facilitates the absorption of the com‑
pound, which translates into higher anticonvulsant ac‑
tivity. NRG‑DM certainly deserves further research in 
the treatment of generalized seizures, and especially 
in the treatment of drug‑resistant focal seizures (Com‑
pans et al., 2018).
Apigenin
Apigenin (4’,5,7‑trihydroxyflavone, Fig. 3) is one of 
the most common flavonoids in plants and belongs to 
the flavone subclass. It has been shown, that the main 
source of the apigenin are plants belonging to Aster-
aceae, such as Artemisia (Ornano et al., 2016), Achillea 
(Venditti et al., 2015; 2016), Matricaria (Sharifi‑Rad et 
al., 2018) and Tanacetum (Venditti et al., 2018). Apigen‑
in has received particular interest because of its anx‑
iolytic, sedative, neuroprotective, anticonvulsant and 
antidepressant properties (Ali et al., 2017). Interesting‑
ly, apigenin can also ameliorate memory dysfunction 
linked to Alzheimer’s disease (Zhao et al., 2013).
Studies by Avallone et al. (2000) determining a po‑
tent anticonvulsant efficacy of apigenin in picrotox‑
in‑induced seizures in Sprague‑Dawley male rats indi‑
cated, that apigenin at doses of 25 and 50 mg/kg ad‑
ministered 15 min before picrotoxin (6 and 8 mg/kg) 
delayed the onset of convulsions.
Interestingly, apigenin administrated for five days 
(25‑50 mg/kg) followed by a KA injection on the last 
day, was shown to reduce both the number and dura‑
tion of seizures in mice (Han et al., 2012). Moreover, 
apigenin was found to block KA‑induced electroen‑
cephalogram discharge activity in the cerebral cortex. 
Cresol violet staining of the brain sections of KA‑treat‑
ed mice showed that KA causes the loss of approximate‑
ly 20% of neurons, whereas apigenin administration af‑
Fig. 3. Structure of apigenin.
Fig. 2. Structure of naringenin.
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ter KA treatment for 5 days rescued about 32‑40% of the 
neuronal loss in the CA3 region. Additionally, apigenin 
(25‑50 mg) in dose‑dependent manner reversed the re‑
duction of glutathione (GSH) levels induced by KA in 
hippocampus tissues. In vitro studies on primary hip‑
pocampal cell culture indicated that apigenin inhibited 
KA‑induced excitotoxicity in a dose‑dependent manner 
as measured by 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑di‑
phenyltetrazolium bromide (MTT) test. Moreover, api‑
genin (5, 20, 60 µM) treatment dose‑dependently inhib‑
ited intracellular reactive oxygen species (ROS) eleva‑
tions in cultured hippocampal neurons. Other in vitro 
studies using SH‑SY5Y cells indicated apigenin’s neuro‑
protection against oxidative stress‑induced cell death 
by blocking caspase‑3 activity and glutamate‑induced 
neurotoxicity by reducing NMDA receptor‑mediated 
responses, which was demonstrated in cultured corti‑
cal neurons (Losi et al., 2004). In addition, apigenin was 
reported to inhibit the influx of extracellular Ca2+ and 
release of intracellular Ca2+ in the rat thoracic aorta 
and NMDA or gamma‑aminobutyric acid (GABA) recep‑
tors channels (Ko et al., 1991).
Luteolin
Luteolin (3’,4’,5,7‑tetrahydroxy flavone, Fig. 4) 
also belongs to the group of flavones. This compound 
is present in herbs such as thyme, chamomile, celery 
and green peppers. It can also be found in vegetables 
and fruits such as parsley, celery, broccoli, apples, on‑
ion leaves (Miean et al., 2001; Mencherini et al., 2007). 
Plants rich in luteolin have been used in the treatment 
of hypertension, inflammatory diseases and cancer 
(Harborne and Williams, 2000). The blood‑brain bar‑
rier is permeable to luteolin, which makes it useful 
in the treatment of diseases of the central nervous 
system, including brain cancer (Wruck et al., 2007). 
Shaikh et al. (2013) indicated no anticonvulsant effect 
of doses (0.3‑10 mg/kg) of luteolin in the 6 Hz seizure 
model, PTZ‑induced seizure test, maximal electro‑
shock (MES) tests as well as in PILO model with sec‑
ond hit PTZ seizure model in mice. On the other hand, 
Tambe and colleagues (2015) evaluated the antiepi‑
leptic potential of luteolin isolated from Eclipta alba 
in PTZ‑induced seizure test in mice. Obtained results 
showed that the administration of luteolin at a dose 
of 10 or 20 mg/kg delayed the occurrence of myoc‑
lonic seizures, clonic seizures and extension of the 
hind limbs in comparison with the PTZ control ani‑
mals. In addition, the above doses showed 100% pro‑
tection against PTZ‑induced mortality. The efficacy 
was comparable to that of diazepam, suggesting that 
luteolin is anti‑epileptic in the PTZ‑induced seizure 
test in a dose‑dependent manner. 
Zhen et al. (2016) studied the anticonvulsant effect 
of luteolin in the PTZ test in rats. They showed that 
initial treatment with luteolin at a dose of 100 mg/kg 
increased seizure delay, reduced the mean seizure du‑
ration and seizure severity compared to the PTZ group. 
Mortality in the PTZ group was 33.3%, while in the 
PTZ+100 mg/kg luteolin rats it decreased to 8.3%. De‑
spite the fact that luteolin did not completely inhibit 
seizures, the results of Nissel’s hippocampus staining 
and the Morris water maze behavioral test showed 
a significant reduction in the neurological damage and 
cognitive deficits associated with daily seizures. Bio‑
chemical studies indicated that the neuroprotective ef‑
fect of luteolin on seizure‑induced cognitive dysfunc‑
tion was exerted by inhibition of ROS production and 
increased phosphoactivation of the cyclic AMP binding 
protein (CREB) pathway and expression of derived neu‑
rotrophic factor (BDNF) in the hippocampus (Zhen et 
al., 2016). 
Interesting results were shown by Smilin Bell 
Aseervatham (2020) studying Passiflora caerulea (PCAE), 
which contains polyphenol compounds such as ginse‑
noside, naringenin, chrysoeriol 8‑c‑glucoside, luteo‑
lin‑6‑C‑glucoside, apigenin‑6,8‑di‑C‑β‑D‑glucopyrano‑
side. PCAE (200 mg/kg) significantly delayed the onset 
of seizures and reduced the duration of clonic seizures 
compared to the PCAE group (100 mg/kg) and diaze‑
pam in the mouse PILO model of epilepsy. Furthermore, 
PCAE‑treated mice showed an improvement in cogni‑
tive function. It is likely that the antioxidant substanc‑
es contained in PCAE have a protective effect on PI‑
LO‑induced seizures by neutralizing oxidative damage 
(Smilin Bell Aseervatham et al., 2020).
Epigallocatechin
Epigallocatechin gallate (EGCG, 2R, 3R‑3’,4’,5,5’,7‑pen‑
tahydroxy flavan‑3‑yl gallate, Fig. 5) is classified in hy‑
droxylated flavans. It constitutes 50% of all polyphenols Fig. 4. Structure of luteolin.
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contained in green tea, but also in chocolate and wine 
(Lin et al., 2003; Del Rio et al., 2004; Voung et al., 2010). It 
has many beneficial properties, such as antioxidant, an‑
ti‑inflammatory and anti‑apoptotic effects (Khalatbary 
et al., 2018; He et al., 2018). A neuroprotective effect of 
EGCG was found in Alzheimer’s disease, Parkinson’s dis‑
ease, ischemic stroke and spinal cord injury (Cano et al., 
2019; Zhou et al., 2019). 
Xie et al. (2012) assessed the effect of EGCG (25, 
50 mg) on PTZ‑induced kindling in rats. The study 
showed that EGCG dose‑dependently inhibited the kin‑
dling progress. In addition, EGCG reduced cognitive 
deficits and oxidative damage caused by PTZ kindling. 
Therefore, EGCG may be a potential antiepileptic agent. 
Results obtained by Xie et al. (2012) are consistent with 
previous Park and coworkers studies (2001), where 
EGCG (10 mg) administered for 7 days has prevented 
cocaine‑induced seizures and protected against death 
as well as with earlier experimental models of epilep‑
sy induced by intracortical injection of Fe‑ions, where 
EGCG prevented or slowed the onset of epilepsy (Yokoi 
et al., 1989). 
Qu et al. (2019) examined the effects of EGCG after 
status epilepticus (SE) on behavior in the rat lithium‑pi‑
locarpine model of TLE. Obtained results showed that 
EGCG treatment after SE tended to reduce the frequen‑
cy of spontaneous recurrent seizures and the duration 
of the seizure, partially attenuating the hippocampal 
late‑phase long‑term potentiation recording impair‑
ment caused by epilepsy. Importantly, histopatholog‑
ical staining of the rat brain showed that after EGCG 
treatment, the number of surviving pyramidal neurons 
significantly increased in the CA1 and CA3 regions of 
the hippocampus, indicating that EGCG has a neuropro‑
tective effect. EGCG was shown to reduce spontaneous 
chronic seizures by reducing the expression of inflam‑
matory factors such as TLR4, NF‑κB and IL‑1β expres‑
sion, which shows that the anti‑inflammatory effect 





yl]oxan‑2‑yl]oxy‑2,3‑dihydrochromen‑4‑one, Fig. 6) 
belongs to flavanones and is mainly found in lemons 
and oranges. Hesperidin has been shown to have neu‑
roprotective, anti‑inflammatory, analgesic, anti‑bacte‑
rial, anti‑fungal, anti‑viral, anti‑hypercholesterolemic 
and anti‑cancer properties (Sudha et al., 2001; Cho et 
al., 2006). Kumar et al. (2014) assessed the effects of 
hesperidin alone and in combination with gabapentin 
and diazepam in the mouse PTZ‑induced epilepsy. Ob‑
tained results indicated that administration of hesper‑
idin (200 mg/kg) 30 min before PTZ administration sig‑
nificantly delayed the onset of seizures. A lower dose of 
hesperidin (100 mg/kg) in combination with diazepam 
(0.2 mg/kg) or gabapentin (10 mg/kg) has also been 
shown to increase the protective effect compared to di‑
azepam and gabapentin used alone. These results sug‑
gest that neuroprotective effects of hesperidin against 
PTZ‑induced convulsions may be related to its antioxi‑
dant properties and the synergy with the ligands at the 
GABAA‑benzodiazepines receptors. Results obtained 
from other studies using an aqueous extract made of 
Citrus aurantium tree leaves containing hesperidin, 
neohesperidin and neohesperidindihydochalcone con‑
firmed anticonvulsant properties of hesperidin against 
PTZ seizures in adult zebrafish (Rosa‑Falero et al., 
2015). C. aurantium extract at a dose of 28 mg/ml, gave 
maximum protective effect with very limited toxic ef‑
fects. Moreover, in vitro results using ligand binding as‑
say showed a significant reduction of [(3)H] Glu binding 
Fig. 5. Structure of epigallocatechin.
Fig. 6. Structure of hesperidin.
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indicating an interaction with glutamate receptors, in 
particular with NMDA receptors and mGluR II, which 
suggests that the extract may be an antagonist at the 
glutamate binding site (Rosa‑Falero et al., 2015).
Quercetin
Quercetin (3,3,4,4,7‑pentahydroxy flavone, Fig. 7), 
a natural flavonoid classified as flavonols. Quercetin is 
found in the apples, blueberries, nuts, grapes, onions 
or chamomile (Srivastava et al., 2010). Nassiri‑Asl et 
al. (2013) investigated the possible effects of quercetin 
on oxidative stress and memory retrieval in rat PTZ 
kindling model. Obtained results indicated that pre‑
treatment with 50 mg/kg of quercetin attenuated sei‑
zure severity from the beginning of the kindling pro‑
cedure by lowering the mean seizure stages compared 
to the control group. Moreover, quercetin at dose of 
50 mg/kg significantly increased the step‑through la‑
tency of the passive avoidance response compared to 
the control rats.
Nieoczym et al. (2014) investigated the effects of 
routine and quercetin in some selected mouse epilep‑
sy models, (6 Hz seizure, maximal electroshock seizure 
threshold MEST and intravenous (iv) PTZ threshold sei‑
zure tests). Rutine and quercetin (400 mg/kg) showed 
statistically significant anticonvulsant effect in the 
6 Hz seizure test. There was no effect on thresholds in 
MEST and iv PTZ tests in mice. Moreover, they evaluat‑
ed the effect of quercetin on the anticonvulsant effect 
of two AEDs, i.e., valproic acid (VPA) and levetiracetam 
(LEV) in a 6 Hz mouse model. Obtained results showed 
no significant impact of quercetin on the AEDs anticon‑
vulsant efficacy. Similarly, no side effects in behavior 
(long‑term memory, muscle strength or motor coordi‑
nation) were observed.
Sefil et al. (2014) showed that quercetin administra‑
tion (10 and 20 mg/kg i.p.) reduced generalized seizure 
duration in PTZ (45 mg/kg i.p.) induced seizures in 
rats, whereas in picrotoxin induced seizures was inef‑
fective. Quercetin also significantly decreased the sei‑
zure severity score and prolonged the onset of seizure 
at 10 mg/kg dose in PTZ induced seizure.
Furthermore, quercetin combined with LEV dose 
dependently attenuated depressive behavior in PTZ 
kindling mice (Singh et al., 2017). Long‑term treat‑
ment with LEV without quercetin significantly reduced 
seizure severity, but exacerbated depressive behavior 
in mice with epilepsy and comorbid depression. This 
is due to the facts that LEV treatment of PTZ mice al‑
ters the kynureuin (KYN) and tryprophan (TRP) ratio 
in both cortical and hippocampal areas of the mouse 
brain, while LEV + quercetin treatment restores KYN: 




dropyran‑2‑carboxylic acid, Fig. 8), is a flavone gly‑
coside found in the plant species Scutellaria. It has the 
following pharmacological properties: anti‑tumor, an‑
tioxidant, antibacterial (Huang et al., 2019). Research 
by Liu et al. (2012), indicated anticonvulsant and 
neuroprotective effects of this compound on pilocar‑
pine‑induced epileptic model in rats. They showed that 
pretreatment baicalin (100 mg) delayed PILO‑induced 
seizures in rats as well as decreased animal mortality. 
Additionally, baicalin reversed the changes in oxidative 
stress levels in the hippocampus (significantly reduced 
nitrite, glutathione and lipid peroxidation) compared 
to the PILO group. Immunihistochemical studies (Nis‑
Fig. 7. Structure of quercetin. Fig. 8. Structure of baicalin.
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sel, Fluoro‑Jade B and TUNEL staining) showed that bai‑
calin protected the hippocampus against neuronal loss, 
apoptosis and pilocarpine‑induced degeneration. Liao 
et al. (2016) demonstrated anti‑apoptotic properties 
of baicalin and proved that it protects against damage 
to the hippocampus in mice after KA‑induced SE. Re‑
search indicates a decrease in the expression of miR‑49 
responsible for neuronal death and an increase in the 
level of Bcl‑2 (an anti‑apoptotic protein). It can be con‑
cluded that baicalin has a protective effect in SE and 
could become a potential supplement in brain damage 
prevention and, with further research, the treatment 
of epilepsy.
Toxicity studies
Since flavonoids are of great interest due to their 
broad spectrum of activity, they have also been 
tested for toxicity. Liang et al. (2017) assessed the 
toxicity of the flavonoid fraction from Lithocarpus 
polystachyus in rodents. In the case of acute toxici‑
ty, doses of 5000 mg/kg were used, and in the case of 
sub‑chronic toxicity, doses were established at 0, 70, 
140, 560 mg/kg for 26 weeks. The dose of 5000 mg/kg 
caused no mortality or any significant toxicity symp‑
toms. In the sub‑chronic toxicity experiment in rats 
no behavioral changes, convulsions, coma, or eating 
problems were observed. Analysis of blood coagula‑
tion parameters and biochemical parameters (creat‑
inine, alkaline phosphatase, glucose, total protein, 
alanine aminotransferase, aspartate aminotransfer‑
ase, bilirubin, total cholesterol, triglycerides) showed 
no significant changes in comparison to the control. 
Hematology only showed an increase in white blood 
cell (WBC) levels compared to the control. WBC levels 
were still normal. Increasing the level of WBC can help 
to strengthen the immune function of the body. Histo‑
pathological examinations did not reveal any patho‑
logical changes within organs. Peng and coworkers 
(2016) studied the toxicity of corn silk flavonoids in 
mice. General clinical signs, mortality, hematological, 
biochemical and histopathological parameters were 
examined. The analysis of the results did not show any 
significant changes compared to the control group. 
Research shows that the use of corn silk as functional 
food is safe. 
CONCLUSIONS
Despite high availability of several generations of 
AEDs, patients resistant to a one drug treatment only 
require an additional anticonvulsant, which carries 
the risk of increasing side effects. Flavonoids were 
shown to have a strong pharmacological effect and 
a wide spectrum of activity. In the light of the results 
of numerous in vivo studies, there is no doubt that due 
to the prevalence of flavonoids in the plant world and 
the presence of vegetables and fruits in the diet, these 
compounds are of great importance in the prevention 
of many civilization diseases and could prove effective 
as an add‑on therapy for epilepsy. Thus, flavonoids 
can be useful for developing new therapeutic strate‑
gies for treating epilepsy. Although antiepileptic ef‑
fects of flavonoids have been verified in preclinical 
studies, there is a great need for including flavonoids 
as antiepileptic agents in clinical trials.
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